RU2729112C2 - Трансгенные генетические метки и способы применения - Google Patents

Трансгенные генетические метки и способы применения Download PDF

Info

Publication number
RU2729112C2
RU2729112C2 RU2016143384A RU2016143384A RU2729112C2 RU 2729112 C2 RU2729112 C2 RU 2729112C2 RU 2016143384 A RU2016143384 A RU 2016143384A RU 2016143384 A RU2016143384 A RU 2016143384A RU 2729112 C2 RU2729112 C2 RU 2729112C2
Authority
RU
Russia
Prior art keywords
cells
polypeptide
seq
domain
her2
Prior art date
Application number
RU2016143384A
Other languages
English (en)
Russian (ru)
Other versions
RU2016143384A3 (enExample
RU2016143384A (ru
Inventor
Майкл К. ДЖЕНСЕН
Адам ДЖОНСОН
Original Assignee
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2729112(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) filed Critical Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют)
Publication of RU2016143384A publication Critical patent/RU2016143384A/ru
Publication of RU2016143384A3 publication Critical patent/RU2016143384A3/ru
Application granted granted Critical
Publication of RU2729112C2 publication Critical patent/RU2729112C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
RU2016143384A 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения RU2729112C2 (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201461977751P 2014-04-10 2014-04-10
US61/977,751 2014-04-10
US201461986479P 2014-04-30 2014-04-30
US61/986,479 2014-04-30
US201462058973P 2014-10-02 2014-10-02
US62/058,973 2014-10-02
US201462088363P 2014-12-05 2014-12-05
US62/088,363 2014-12-05
US201462089730P 2014-12-09 2014-12-09
US62/089,730 2014-12-09
US201462090845P 2014-12-11 2014-12-11
US62/090,845 2014-12-11
PCT/US2015/024895 WO2015157399A1 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020124619A Division RU2822461C1 (ru) 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения

Publications (3)

Publication Number Publication Date
RU2016143384A RU2016143384A (ru) 2018-05-11
RU2016143384A3 RU2016143384A3 (enExample) 2018-11-30
RU2729112C2 true RU2729112C2 (ru) 2020-08-04

Family

ID=54288361

Family Applications (5)

Application Number Title Priority Date Filing Date
RU2016143384A RU2729112C2 (ru) 2014-04-10 2015-04-08 Трансгенные генетические метки и способы применения
RU2016143385A RU2751921C2 (ru) 2014-04-10 2015-04-08 Продукты определенного состава, содержащие генетически модифицированные т-клетки
RU2016143381A RU2752275C2 (ru) 2014-04-10 2015-04-08 Способ и композиции для клеточной иммунотерапии
RU2016143389A RU2016143389A (ru) 2014-04-10 2015-04-08 Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
RU2016143388A RU2751920C2 (ru) 2014-04-10 2015-04-08 Экспрессия трансгенов, регулируемая лекарственным средством

Family Applications After (4)

Application Number Title Priority Date Filing Date
RU2016143385A RU2751921C2 (ru) 2014-04-10 2015-04-08 Продукты определенного состава, содержащие генетически модифицированные т-клетки
RU2016143381A RU2752275C2 (ru) 2014-04-10 2015-04-08 Способ и композиции для клеточной иммунотерапии
RU2016143389A RU2016143389A (ru) 2014-04-10 2015-04-08 Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
RU2016143388A RU2751920C2 (ru) 2014-04-10 2015-04-08 Экспрессия трансгенов, регулируемая лекарственным средством

Country Status (19)

Country Link
US (12) US10865242B2 (enExample)
EP (8) EP4056201A1 (enExample)
JP (12) JP6772068B2 (enExample)
KR (8) KR102463529B1 (enExample)
CN (7) CN112877291A (enExample)
AU (8) AU2015243849B2 (enExample)
BR (3) BR112016023517A2 (enExample)
CA (5) CA2945308C (enExample)
ES (2) ES2867224T3 (enExample)
IL (5) IL297591B2 (enExample)
MX (6) MX389797B (enExample)
MY (4) MY186846A (enExample)
NZ (3) NZ739448A (enExample)
PH (4) PH12016502010B1 (enExample)
RU (5) RU2729112C2 (enExample)
SA (1) SA516380056B1 (enExample)
SG (8) SG11201608392WA (enExample)
WO (5) WO2015157432A1 (enExample)
ZA (3) ZA201607061B (enExample)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548667C (zh) * 2003-01-20 2009-10-14 日本瑞翁株式会社 层合件及其制造方法
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
PL3071223T3 (pl) * 2013-11-21 2021-08-16 Autolus Limited Komórka
ES2867224T3 (es) 2014-04-10 2021-10-20 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Etiquetas genéticas transgénicas y métodos de uso
PT4219687T (pt) 2014-04-23 2024-10-02 Juno Therapeutics Inc Métodos para isolamento, cultura, e manipulação genetica de populações de células imunes para terapêutica adotiva
GB2540694A (en) 2014-04-29 2017-01-25 Seattle Children's Hospital (Dba Seattle Children's Res Institute) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
CN107106610A (zh) 2014-10-20 2017-08-29 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
AU2015339744B2 (en) 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3766895B1 (en) 2014-12-03 2024-07-10 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
BR112017011914A2 (pt) 2014-12-05 2018-02-27 Memorial Sloan-Kettering Cancer Center ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
FI3240805T3 (fi) 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
KR20170128234A (ko) 2015-01-16 2017-11-22 주노 쎄러퓨티크스 인코퍼레이티드 Ror1에 특이적인 항체 및 키메라 항원 수용체
JP6947647B2 (ja) * 2015-02-24 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 遺伝子改変ｔ細胞の選択方法
EP4091616A1 (en) 2015-02-27 2022-11-23 iCell Gene Therapeutics LLC Chimeric antigen receptors (car) targeting hematologic malignancies, compositions and methods of use thereof
CA2981751A1 (en) * 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
IL287718B2 (en) 2015-06-25 2025-05-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods for using them
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP7162530B2 (ja) 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
CN108601849A (zh) * 2015-09-22 2018-09-28 尤利乌斯·马克西米利安维尔茨堡大学 一种在淋巴细胞中高水平的和稳定的基因转移的方法
BR112018006991A2 (en) 2015-10-06 2018-10-16 City Of Hope psca-targeted chimeric antigen receptors
EP3364987A4 (en) * 2015-10-23 2019-05-15 The Regents of the University of Colorado, a Body Corporate FORECAST AND TREATMENT OF DISCONTINUED CARCINOMENAS
KR20180069067A (ko) 2015-10-30 2018-06-22 엔비이-테라퓨틱스 아게 안티-ror1 항체
WO2017079703A1 (en) * 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
CN108603200B (zh) * 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
CA3004665C (en) * 2015-12-14 2021-08-24 GenomeFrontier Therapeutics, Inc. Transposon system, kit comprising the same, and uses thereof
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3430549A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US12060394B2 (en) 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
KR20240111740A (ko) 2016-06-08 2024-07-17 프레시전 인코포레이티드 Cd33 특이적 키메라 항원 수용체
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
AU2017343780B2 (en) 2016-10-13 2023-08-31 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018075941A1 (en) * 2016-10-21 2018-04-26 Washington University Ap4 and methods of promoting t cell activation
CA3044261A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
AU2017375630B2 (en) * 2016-12-12 2023-12-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN106800601B (zh) * 2017-01-19 2021-04-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
WO2018134691A2 (en) * 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
KR20250029276A (ko) 2017-03-14 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
CN106963945A (zh) * 2017-03-27 2017-07-21 山东兴瑞生物科技有限公司 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
CA3063695A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
WO2018218038A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CA3062130A1 (en) * 2017-05-26 2019-11-22 Green Cross Lab Cell Corporation Method for culturing natural killer cell, using transformed t cell
AU2018275894B2 (en) * 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
CN107335054B (zh) * 2017-06-30 2021-01-15 山东兴瑞生物科技有限公司 一种慢性乙肝治疗性dc疫苗
CA3071212C (en) 2017-08-07 2023-12-12 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
CN111133104A (zh) * 2017-08-11 2020-05-08 特里比奥迪卡有限责任公司 通过模板化组装生成结合到识别分子的表位的方法
US11643468B2 (en) * 2017-08-23 2023-05-09 Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-Gemeinschaft Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders
JP2020536531A (ja) * 2017-09-26 2020-12-17 ロングウッド ユニバーシティーＬｏｎｇｗｏｏｄ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法としてのｐｄ１特異的キメラ抗原受容体
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
US11771718B2 (en) 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US12258580B2 (en) * 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
EP3703750B1 (en) 2017-11-01 2024-12-04 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
CN120608077A (zh) 2017-11-10 2025-09-09 美国政府(由卫生和人类服务部的部长所代表) 靶向肿瘤抗原的嵌合抗原受体
WO2019099483A1 (en) * 2017-11-14 2019-05-23 Memorial Sloan-Kettering Cancer Center Il-36 secreting immunoresponsive cells and uses thereof
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
WO2019144091A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN108383914A (zh) * 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
EP3765601A1 (en) * 2018-03-16 2021-01-20 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
DK3793565T3 (en) 2018-05-14 2022-03-07 Gilead Sciences Inc Mcl-1-inhibitorer
CA3100446A1 (en) 2018-05-15 2019-11-21 Carsgen Therapeutics Co., Ltd. Genetically engineered cell and application thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CN113039206A (zh) * 2018-08-31 2021-06-25 西雅图儿童医院（Dba西雅图儿童研究所） 包含b7h3嵌合抗原受体的方法和组合物
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
JP7152080B2 (ja) * 2018-10-19 2022-10-12 カーテクセル インコーポレイテッド 抗ｌ１ｃａｍ抗体又はその抗原結合断片、融合タンパク質、キメラ抗原受容体ポリペプチド、核酸分子、組換えベクター、効果器細胞、及び薬剤学的組成物
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3892721A4 (en) 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
JP2022513062A (ja) * 2018-11-16 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
KR20210117260A (ko) * 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
KR20210110811A (ko) * 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
WO2020113234A1 (en) * 2018-11-30 2020-06-04 Celularity, Inc. Placenta-derived allogeneic car-t cells and uses thereof
CA3124103A1 (en) * 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
US20220195414A1 (en) * 2019-04-08 2022-06-23 Russell Biotech, Inc. Improved Manufacturing Procedures for Cell Based Therapies
CN110010222A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基于精准用药知识库的基因身份识别系统
CN110010200A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基因身份识别系统
CN109994156A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含报告模板信息管理模块的精准用药智能报告系统
CN109979545A (zh) * 2019-04-16 2019-07-05 北京中佰耀因医药科技有限公司 一种含样本状态信息管理模块的精准用药智能报告系统
CN109994180A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含基因位点信息管理模块的精准用药智能报告系统
CN109994176A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含样本类型信息管理模块的精准用药智能报告系统
CN109872792A (zh) * 2019-04-16 2019-06-11 北京中佰耀因医药科技有限公司 一种用于指导精准用药的基因检测智能报告系统
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20200384029A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
WO2020257309A1 (en) * 2019-06-17 2020-12-24 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
AU2020295715A1 (en) * 2019-06-19 2022-02-17 Julius-Maximilians-Universität Würzburg Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CN110608991B (zh) * 2019-09-09 2022-04-29 浙江普罗亭健康科技有限公司 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
EP4121447A1 (en) 2020-03-20 2023-01-25 Lyell Immunopharma, Inc. Novel recombinant cell surface markers
EP4143194A1 (en) 2020-05-01 2023-03-08 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
GB202007169D0 (en) * 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN115803038A (zh) * 2020-06-08 2023-03-14 西雅图儿童医院（Dba西雅图儿童研究所） 抗cd171嵌合抗原受体
WO2022007938A1 (en) * 2020-07-09 2022-01-13 Nanjing Legend Biotech Co., Ltd. Engineering gamma delta t cells with interleukin-36 for immunotherapy
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
US20240043544A1 (en) * 2020-12-08 2024-02-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022155526A2 (en) * 2021-01-15 2022-07-21 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Hybrid and truncated immune cell proteins
EP4298120A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023025208A1 (zh) * 2021-08-24 2023-03-02 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP2024541979A (ja) 2021-10-29 2024-11-13 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250228940A1 (en) * 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
DK4245756T3 (da) 2022-03-17 2024-10-21 Gilead Sciences Inc Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4504243A1 (en) * 2022-04-01 2025-02-12 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
EP4532701A1 (en) * 2022-05-27 2025-04-09 Autolus Limited Method
TW202413647A (zh) * 2022-06-10 2024-04-01 俄羅斯聯邦商拜奧卡德聯合股份公司 具有啟動子活性之核酸及其用途
WO2024006702A1 (en) * 2022-06-27 2024-01-04 Foundation Medicine, Inc. Methods and systems for predicting genotypic calls from whole-slide images
CR20240570A (es) 2022-07-01 2025-03-03 Gilead Sciences Inc Compuestos de cd73
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
CN120435300A (zh) * 2022-12-15 2025-08-05 莱兰斯坦福初级大学评议会 人t细胞中的非同源依赖性靶向dna插入
AU2023408894A1 (en) * 2022-12-20 2025-06-12 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
EP4653467A1 (en) * 2023-01-19 2025-11-26 Wuhan Zhaozhi Biotechnology Co., Ltd. Car molecule, cell or exosome containing same, and use thereof
US20240290628A1 (en) * 2023-02-24 2024-08-29 American Air Liquide, Inc. Etching method using oxygen-containing hydrofluorocarbon
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
CN116844685B (zh) * 2023-07-03 2024-04-12 广州默锐医药科技有限公司 一种免疫治疗效果评估方法、装置、电子设备及存储介质
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056894A2 (en) * 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US20020111474A1 (en) * 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
EP0650367A4 (en) 1992-06-01 1998-04-15 New England Medical Center Inc BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES.
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040037816A1 (en) 1999-04-15 2004-02-26 Monash University Graft acceptance through manipulation of thymic regeneration
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
JP4045713B2 (ja) 2000-01-31 2008-02-13 松下電器産業株式会社 自動機用溶接機
GB0015119D0 (en) * 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) * 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
WO2002097050A2 (en) 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
IL160933A0 (en) 2001-09-18 2004-08-31 Proteologics Inc Methods and compositions for treating ?cap associated diseases
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
MXPA04009809A (es) 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
EP2289559B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060160090A1 (en) 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
CN1809277A (zh) * 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的移植物耐受
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
RU2397249C2 (ru) 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
EP1680447A2 (en) 2003-10-24 2006-07-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Orthogonal gene switches
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
DE202005002921U1 (de) 2005-02-23 2005-04-21 Magcode Ag Verbindungssystem, insbesondere elektrisches Verbindungssystem
KR20080036015A (ko) 2005-06-01 2008-04-24 주식회사 바이오텍 아이 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
US20080044413A1 (en) 2005-12-21 2008-02-21 Hammond Scott A EphA2 BiTE molecules and uses thereof
AU2007254508B2 (en) 2006-05-22 2012-03-22 Hiprocell, Llc Protein production using eukaryotic cell lines
US8148129B2 (en) 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) * 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2009013359A2 (en) * 2007-07-25 2009-01-29 Fraunhofer Gesellschaft Zur Förderung Der Angewandten Forschung E. V. Self coupling recombinant antibody fusion proteins
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EP2279253B1 (en) * 2008-04-09 2016-11-16 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PT3006459T (pt) 2008-08-26 2021-11-26 Hope City Método e composições para funcionamento melhorado de efetores antitumorais de células t
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
US8329882B2 (en) * 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
EP2438443A4 (en) 2009-06-02 2012-07-25 Targeted Molecular Diagnostics Llc METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2)
US9873035B2 (en) * 2009-07-09 2018-01-23 Cfph, Llc Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2665521A4 (en) * 2011-01-18 2014-09-03 Univ Pennsylvania COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
ES2841983T3 (es) * 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
EP2697367B1 (en) 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
EP2723773B1 (en) * 2011-06-22 2018-02-28 F. Hoffmann-La Roche AG Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
AU2012325915A1 (en) 2011-10-20 2014-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
AU2013222288A1 (en) * 2012-02-22 2014-08-14 The Trustees Of The University Of Pennsylvania Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
KR102086874B1 (ko) 2012-04-11 2020-03-10 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
EP2854866A4 (en) 2012-05-30 2015-12-23 Baylor College Medicine SUPERHELIC MINI-SECTORS AS A TOOL FOR DNS REPAIR, CHANGE AND REPLACEMENT
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
CN104350709B (zh) 2012-06-01 2018-03-13 日本电气株式会社 交换机系统、线路卡、交换卡、fdb学习方法及fdb学习调停方法
IL269270B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9598489B2 (en) * 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6401704B2 (ja) 2012-10-10 2018-10-10 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞を修飾する化合物およびその使用
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
EP3456818B1 (en) 2013-03-07 2020-05-20 Baylor College of Medicine Targeting cd138 in cancer
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
AU2014265487B2 (en) * 2013-05-14 2020-10-22 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
RU2733652C2 (ru) 2013-10-31 2020-10-06 Фред Хатчинсон Кэнсер Рисерч Сентер МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ
PL3071223T3 (pl) 2013-11-21 2021-08-16 Autolus Limited Komórka
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
US10239948B2 (en) 2013-12-20 2019-03-26 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
BR112016016411A2 (pt) 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
SG10201811816RA (en) 2014-02-14 2019-02-27 Univ Texas Chimeric antigen receptors and methods of making
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
ES2867224T3 (es) 2014-04-10 2021-10-20 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Etiquetas genéticas transgénicas y métodos de uso
KR20200000495A (ko) 2014-05-14 2020-01-02 카르스젠 테라퓨틱스 리미티드 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구
WO2015187528A1 (en) 2014-06-02 2015-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
HK1243631A1 (zh) 2014-10-27 2018-07-20 Fred Hutchinson Cancer Research Center 用於提高过继细胞免疫疗法效力的组合物和方法
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
JP2018517415A (ja) 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド がんを処置するための改変ｎｋ−９２細胞
ES2854731T3 (es) 2015-06-12 2021-09-22 Lentigen Tech Inc Procedimiento para tratar cáncer con células T modificadas genéticamente
JP7162530B2 (ja) 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
CA3013773A1 (en) 2016-02-05 2017-08-10 City Of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
CN109415409B (zh) 2016-04-01 2022-03-15 亘喜生物科技（上海）有限公司 Flag标记的cd19-car-t细胞
TWI779479B (zh) 2016-09-28 2022-10-01 美商凱特製藥公司 抗原結合分子類和使用彼等之方法
US11286291B2 (en) 2016-10-04 2022-03-29 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
AU2017375630B2 (en) 2016-12-12 2023-12-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
KR20210074274A (ko) 2018-08-06 2021-06-21 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물
US10714296B2 (en) 2018-12-12 2020-07-14 Axcelis Technologies, Inc. Ion source with tailored extraction shape
US11104732B2 (en) 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056894A2 (en) * 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AERTGEERTS K. et al., Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein, Journal of Biological Chemistry, 2011, V. 286, N. 21, p.18756-18765. *
CHO H. S. et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 2003, V. 421, N. 6924, p.756-760. *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein engineering, 2000, V. 13, N. 8, p.575-581. *
GARRETT J. T. et al., Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu, The Journal of Immunology, 2007, V. 178, N. 11, p.7120-7131. *
HUDECEK M. et al. Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells, Clinical Cancer Research, 2013, V. 19, N. 12, p.3153-3164. *
PAKULA A.A. et al., Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p.289-310. *
WANG X. et al., A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 2011, V. 118, N. 5, p.1255-1263. *
WANG X. et al., A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 2011, V. 118, N. 5, p.1255-1263. HUDECEK M. et al. Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells, Clinical Cancer Research, 2013, V. 19, N. 12, p.3153-3164. AERTGEERTS K. et al., Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein, Journal of Biological Chemistry, 2011, V. 286, N. 21, p.18756-18765. CHO H. S. et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 2003, V. 421, N. 6924, p.756-760. GARRETT J. T. et al., Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu, The Journal of Immunology, 2007, V. 178, N. 11, p.7120-7131. FRANKEL A.E. et al., Characterization of diphtheria fus *
ЛИКАРЬ Ю. Н. и др., Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, c.23-31. *

Also Published As

Publication number Publication date
KR102387243B1 (ko) 2022-04-14
RU2016143388A3 (enExample) 2018-11-30
SG10201808811QA (en) 2018-11-29
MY186846A (en) 2021-08-26
WO2015157384A1 (en) 2015-10-15
KR20220153100A (ko) 2022-11-17
MY185678A (en) 2021-05-30
MX2016013159A (es) 2017-04-27
AU2015243849A1 (en) 2016-11-03
CN106661570A (zh) 2017-05-10
JP6765967B2 (ja) 2020-10-14
JP7062720B2 (ja) 2022-05-06
JP2020195380A (ja) 2020-12-10
CN106574246A (zh) 2017-04-19
WO2015157399A9 (en) 2016-11-24
US20210139583A1 (en) 2021-05-13
AU2015243882C1 (en) 2024-07-25
CA2945302A1 (en) 2015-10-15
EP3129053A1 (en) 2017-02-15
US20170015746A1 (en) 2017-01-19
US20220372140A1 (en) 2022-11-24
IL248243B2 (en) 2024-04-01
AU2015243922B2 (en) 2021-08-05
IL248229B2 (en) 2023-05-01
AU2015243920A1 (en) 2016-11-03
RU2751921C2 (ru) 2021-07-20
CA2945308C (en) 2023-10-31
CN106573969A (zh) 2017-04-19
US20190248891A1 (en) 2019-08-15
US10611837B2 (en) 2020-04-07
EP3129399A4 (en) 2017-11-08
KR102600544B1 (ko) 2023-11-09
CA2945320A1 (en) 2015-10-15
AU2015243927A1 (en) 2016-11-03
EP3129480A1 (en) 2017-02-15
NZ739448A (en) 2019-10-25
SA516380056B1 (ar) 2021-07-04
SG11201608393TA (en) 2016-11-29
RU2016143388A (ru) 2018-05-14
PH12016502010A1 (en) 2017-01-09
PH12016502011A1 (en) 2017-01-09
EP3129405B1 (en) 2021-02-24
US20170267742A1 (en) 2017-09-21
EP3129405A4 (en) 2017-08-09
JP6788573B6 (ja) 2020-12-16
RU2016143384A3 (enExample) 2018-11-30
JP7542270B2 (ja) 2024-08-30
SG10201808833XA (en) 2018-11-29
JP2022184989A (ja) 2022-12-13
ES2880932T3 (es) 2021-11-26
AU2015243922A1 (en) 2016-11-03
AU2015243920B2 (en) 2020-10-08
CA2945308A1 (en) 2015-10-15
JP2021019589A (ja) 2021-02-18
MX395574B (es) 2025-03-25
KR102463529B1 (ko) 2022-11-07
KR20160143762A (ko) 2016-12-14
RU2016143381A3 (enExample) 2018-11-30
US12258397B2 (en) 2025-03-25
BR112016023500B1 (pt) 2024-04-30
NZ758289A (en) 2024-01-26
IL248238B1 (en) 2024-10-01
RU2016143385A3 (enExample) 2018-11-30
JP7402933B2 (ja) 2023-12-21
AU2015243927B2 (en) 2021-09-02
KR20220051024A (ko) 2022-04-25
IL248235A0 (en) 2016-11-30
ZA201607060B (en) 2024-05-30
JP7093385B2 (ja) 2022-06-29
EP3129405A1 (en) 2017-02-15
IL248238A0 (en) 2016-11-30
KR20160138298A (ko) 2016-12-02
RU2016143389A3 (enExample) 2018-12-04
EP3129471A4 (en) 2017-11-08
KR102618955B9 (ko) 2024-08-12
IL248229B1 (en) 2023-01-01
JP2017513470A (ja) 2017-06-01
EP3954708A1 (en) 2022-02-16
US20170029774A1 (en) 2017-02-02
KR20160144431A (ko) 2016-12-16
US10266592B2 (en) 2019-04-23
KR20160144430A (ko) 2016-12-16
CN106573969B (zh) 2021-07-30
CA2945305A1 (en) 2015-10-15
RU2016143384A (ru) 2018-05-11
MX2016013160A (es) 2017-02-09
BR112016023513A2 (pt) 2017-10-17
JP7148580B2 (ja) 2022-10-05
CA2945305C (en) 2023-10-17
BR112016023523A2 (pt) 2017-10-17
AU2021201679A1 (en) 2021-04-08
JP6788573B2 (ja) 2020-11-25
US20210002364A1 (en) 2021-01-07
ZA201607061B (en) 2024-05-30
AU2021200007A1 (en) 2021-03-04
ES2867224T3 (es) 2021-10-20
WO2015157399A1 (en) 2015-10-15
KR102463529B9 (ko) 2024-07-31
MX387465B (es) 2025-03-18
PH12016502009A1 (en) 2017-01-09
IL297591B1 (en) 2025-01-01
CN113528581A (zh) 2021-10-22
MY184163A (en) 2021-03-24
BR112016023507A2 (pt) 2017-10-17
KR20230038310A (ko) 2023-03-17
US12448445B2 (en) 2025-10-21
PH12016502009B1 (en) 2022-07-22
MY192522A (en) 2022-08-25
JP6765968B2 (ja) 2020-10-07
JP2021000117A (ja) 2021-01-07
IL248243A0 (en) 2016-11-30
NZ725081A (en) 2018-02-23
AU2015243882A1 (en) 2016-11-03
KR102509481B1 (ko) 2023-03-10
SG11201608396YA (en) 2016-11-29
CA2945303A1 (en) 2015-10-15
SG11201608392WA (en) 2016-11-29
CN106536558A (zh) 2017-03-22
JP2017513520A (ja) 2017-06-01
AU2021273652A1 (en) 2021-12-16
IL248229A (en) 2016-11-30
EP3943507A1 (en) 2022-01-26
CN112877291A (zh) 2021-06-01
JP7508516B2 (ja) 2024-07-01
AU2015243882B2 (en) 2020-03-12
CN106661570A8 (zh) 2017-07-04
IL248243B1 (en) 2023-12-01
PH12016502011B1 (en) 2022-06-17
EP3129480A4 (en) 2017-08-16
NZ725079A (en) 2018-03-23
KR102618955B1 (ko) 2023-12-27
AU2015243849A9 (en) 2019-07-25
WO2015157386A1 (en) 2015-10-15
KR20160144432A (ko) 2016-12-16
RU2751920C2 (ru) 2021-07-20
RU2016143389A (ru) 2018-05-15
IL297591A (en) 2022-12-01
SG11201608395PA (en) 2016-11-29
MX2016013158A (es) 2017-04-27
US12202897B2 (en) 2025-01-21
JP2021036867A (ja) 2021-03-11
US20220380461A1 (en) 2022-12-01
SG10201808819XA (en) 2018-11-29
JP7106610B2 (ja) 2022-07-26
IL248235B (en) 2021-01-31
IL297591B2 (en) 2025-05-01
EP4056201A1 (en) 2022-09-14
RU2016143385A (ru) 2018-05-15
JP2022153456A (ja) 2022-10-12
WO2015157391A1 (en) 2015-10-15
AU2021201679B2 (en) 2023-05-04
JP6772068B2 (ja) 2020-10-21
KR102387243B9 (ko) 2023-07-10
EP3129471A1 (en) 2017-02-15
US11414486B2 (en) 2022-08-16
JP2017512484A (ja) 2017-05-25
US11155616B2 (en) 2021-10-26
MX2016013149A (es) 2017-04-27
MX2016013144A (es) 2017-04-27
ZA201607053B (en) 2025-03-26
EP3129399B1 (en) 2021-05-26
US10865242B2 (en) 2020-12-15
MX389797B (es) 2025-03-20
CA2945303C (en) 2024-02-13
KR102508166B1 (ko) 2023-03-13
AU2015243849B2 (en) 2020-12-17
US20170152297A1 (en) 2017-06-01
PH12016502010B1 (en) 2023-08-16
JP2017515464A (ja) 2017-06-15
BR112016023517A2 (pt) 2017-10-17
US20180009891A1 (en) 2018-01-11
IL248238B2 (en) 2025-02-01
EP3129399A1 (en) 2017-02-15
BR112016023500A2 (pt) 2017-10-17
RU2752275C2 (ru) 2021-07-26
US20220064292A1 (en) 2022-03-03
JP2022109953A (ja) 2022-07-28
JP2017518037A (ja) 2017-07-06
CN106661570B (zh) 2020-02-07
AU2021200007B2 (en) 2024-08-29
RU2016143381A (ru) 2018-05-11
PH12016502012A1 (en) 2017-01-09
US20210371517A1 (en) 2021-12-02
EP3129053A4 (en) 2017-11-08
CN106535934A (zh) 2017-03-22
MX2022010807A (es) 2022-09-27
WO2015157432A1 (en) 2015-10-15
SG10201808825XA (en) 2018-11-29
KR102730216B1 (ko) 2024-11-14

Similar Documents

Publication Publication Date Title
AU2021201679B2 (en) Transgene genetic tags and methods of use
US20250230217A1 (en) Methods for improving the efficacy and expansion of immune cells
RU2700765C2 (ru) Способ и композиции для клеточной иммунотерапии
CA2981751A1 (en) Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
RU2822461C1 (ru) Трансгенные генетические метки и способы применения
HK40069668A (en) Transgene genetic tags and methods of use
HK1233273B (en) Transgene genetic tags and methods of use
BR112016023507B1 (pt) Polipeptídeo isolado que compreende um domínio extracelular de um polipeptídeo her2